Unnamed Onychomycosis Program

About Turn Therapeutics

Turn Therapeutics is pioneering a new category of precision therapeutics that combine biologic-level efficacy with localized delivery, beginning in dermatologic inflammation. The company's core strategy is to develop topical treatments that act precisely where disease occurs, avoiding the systemic side effects associated with injectable biologics. In addition to its clinical pipeline, Turn has a capital-efficient business model that includes strategic partnerships generating non-dilutive revenue and commercial sales from FDA-cleared wound care products. The company is advancing late-stage clinical programs in eczema and onychomycosis while pursuing global health initiatives in thermostable vaccine delivery.

Therapeutic Areas